A novel peptide (GX1) homing to gastric cancer vasculature inhibits angiogenesis and cooperates with TNF alpha in anti-tumor therapy

BMC Cell Biology

Volumn 10, Issue , 2009, Pages 63-

  Chen, Bei ^a   Cao, Shanshan ^a   Zhang, Yingqi ^b   Wang, Xin ^a   Liu, Jie ^a   Hui, Xiaoli ^a   Wan, Yi ^b   Du, Wenqi ^a   Wang, Li ^a   Wu, Kaichun ^a   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CASPASE 3; CYSTEINYLGLYCYLASPARAGINYLSERYLASPARAGINYLPROPYLLYSYLSERYLCYSTEINE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; EMBRYO; ENDOTHELIUM CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; STOMACH CANCER; TOXICITY TESTING; TUMOR VASCULARIZATION; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELLS, CULTURED; DISEASE PROGRESSION; ENDOTHELIAL CELLS; HUMANS; MICE; MICE, NUDE; OLIGOPEPTIDES; STOMACH NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349606645     PISSN: None     EISSN: 14712121     Source Type: Journal    
DOI: 10.1186/1471-2121-10-63     Document Type: Article

References (35)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
2. Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 2008, 49(Suppl 2):113S-128S.
3. Corti A, Curnis F, Arap W, Pasqualini R. The neovasculature homing motif NGR: more than meets the eye. Blood 2008, 112:2628-2635.
4. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW. Genes expressed in human tumor endothelium. Science 2000, 289:1197-1202.
5. Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol 2003, 13:159-167.
6. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 1990, 9:267-282.
7. Hajitou A, Pasqualini R, Arap W. Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc Med 2006, 16:80-88.
8. Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano RJ, Mintz PJ, Ardelt PU, Yao VJ, Vidal CI, Chen L, Flamm A, Valtanen H, Weavind LM, Hicks ME, Pollock RE, Botz GH, Bucana CD, Koivunen E, Cahill D, Troncoso P, Baggerly KA, Pentz RD, Do KA, Logothetis CJ, Pasqualini R. Steps toward mapping the human vasculature by phage display. Nat Med 2002, 8:121-127.
9. Zhi M, Wu KC, Dong L, Hao ZM, Deng TZ, Hong L, Liang SH, Zhao PT, Qiao TD, Wang Y, Xu X, Fan DM. Characterization of a specific phage-displayed Peptide binding to vasculature of human gastric cancer. Cancer Biol Ther 2004, 3:1232-1235.
10. Han Y, Hong L, Wu K, Cao S, He L, Fan D. Expression of vascular-binding peptide CGNSNPKSC in gastric cancer and the identification of its possible receptor. Modern Oncology 2007, 15:458-460.
11. Wang H, Yan Z, Shi J, Han W, Zhang Y. Expression, purification, and characterization of a neovasculature targeted rmhTNF-alpha in Escherichia coli. Protein Expr Purif 2006, 45:60-65.
12. Zhang YQ, Zhao N, Li B, Liu L, Wang ZL, Zhu BE, Yan ZL, Su CZ. Preparation of a novel recombinant human tumor necrosis factor-α by gene engineering technology. Chin J Cell Mol Immunol 2002, 18:402-405.
13. Khodarev NN, Yu J, Labay E, Darga T, Brown CK, Mauceri HJ, Yassari R, Gupta N, Weichselbaum RR. Tumour-endothelium interactions in co-culture: coordinated changes of gene expression profiles and phenotypic properties of endothelial cells. J Cell Sci 2003, 116:1013-1022.
14. Cao S, Wu K, Yan Z, Wan Y, Han Y, Zhao L, Fan D. Cloning, expression and identification of recombinant fusion protein GX1- rmhTNFα. Chin J Cell Mol Immunol 2006, 22:360-362.
15. Lejeune F, Lienard D, Eggermont A, Schraffordt Koops H, Rosenkaimer F, Gerain J, Klaase J, Kroon B, Vanderveken J, Schmitz P. Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma. J Cell Biochem 1994, 56:52-61.
16. Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, Daenen LG, Man S, Xu P, Emmenegger U, Tang T, Zhu Z, Witte L, Strieter RM, Bertolini F, Voest EE, Benezra R, Kerbel RS. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008, 14:263-273.
17. Dy GK, Adjei AA. Systemic cancer therapy: evolution over the last 60 years. Cancer 2008, 113:1857-1887.
18. Field K, Michael M, Leong T. Locally advanced and metastatic gastric cancer: current management and new treatment developments. Drugs 2008, 68:299-317.
19. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008, 8:579-591.
20. Marshall J. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 2006, 107:1207-1218.
21. Zacher AN, Stock CA, Golden JW, Smith GP. A new filamentous phage cloning vector: fd-tet. Gene 1980, 9:127-140.
22. Porkka K, Laakkonen P, Hoffman JA, Bernasconi M, Ruoslahti E. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc Natl Acad Sci USA 2002, 99:7444-7449.
23. Pasqualini R, Koivunen E, Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 1997, 15:542-546.
24. Laakkonen P, Akerman ME, Biliran H, Yang M, Ferrer F, Karpanen T, Hoffman RM, Ruoslahti E. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci USA 2004, 101:9381-9386.
25. Gehlsen KR, Argraves WS, Pierschbacher MD, Ruoslahti E. Inhibition of in vitro tumor cell invasion by Arg-Gly-Asp-containing synthetic peptides. J Cell Biol 1988, 106:925-930.
26. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002, 2:750-763.
27. Rowlinson-Busza G, Epenetos AA. Targeted delivery of biologic and other antineoplastic agents. Curr Opin Oncol 1992, 4:1142-1148.
28. Hui X, Han Y, Liang S, Liu Z, Liu J, Hong L, Zhao L, He L, Cao S, Chen B, Yan K, Jin B, Chai N, Wang J, Wu K, Fan D. Specific targeting of the vasculature of gastric cancer by a new tumor-homing peptide CGNSNPKSC. J Control Release 2008, 131:86-93.
29. Tanaka Y, Abe M, Hiasa M, Oda A, Amou H, Nakano A, Takeuchi K, Kitazoe K, Kido S, Inoue D, Moriyama K, Hashimoto T, Ozaki S, Matsumoto T. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res 2007, 13:816-823.
30. Eliceiri BP, Cheresh DA. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 1999, 103:1227-1230.
31. Lowenstein PR. Clinical trials in gene therapy: ethics of informed consent and the future of experimental medicine. Curr Opin Mol Ther 2008, 10:428-430.
32. Han W, Zhang Y, Yan Z. Construction of a new tumor necrosis factor fusion-protein expression vector for high-level expression of heterologous genes in Escherichia coli. Biotechnol Appl Biochem 2003, 37:109-113.
33. Yamaue H, Tanimura H, Noguchi K, Hotta T, Tani M, Tsunoda T, Iwahashi M, Tamai M, Iwakura S. Chemosensitivity testing of fresh human gastric cancer with highly purified tumour cells using the MTT assay. Br J Cancer 1992, 66:794-799.
34. Milner AE, Levens JM, Gregory CD. Flow cytometric methods of analyzing apoptotic cells. Methods Mol Biol 1998, 80:347-354.
35. Wang L, Wei D, Huang S, Peng Z, Le X, Wu TT, Yao J, Ajani J, Xie K. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 2003, 9:6371-6380.